Skip to main content
. Author manuscript; available in PMC: 2013 Jul 2.
Published in final edited form as: Br J Haematol. 2011 Oct 20;155(4):457–467. doi: 10.1111/j.1365-2141.2011.08882.x

Fig 2.

Fig 2

In vivo and In vitro lenalidomide treatment are associated with upregulation of costimulatory molecules on B-CLL cells. PBMCs were isolated from three patients pre- and post- 7 d treatment with lenalidomide and analysed by flow cytometry for CD19+ cells that express the indicated protein. One representative patient sample is shown (A). s The effect of lenalidomide on modulation of the costimulatory molecules was independent of the dose used. B-CLL cells (CD19+) from six patients were treated in vitro with 10μmol/l of lenalidomide for 48 h and surface expression of costimulatory molecules analyzed by flow cytometry (B).